This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Plasmodium Falciparum Malaria
and you are
between 15 and 60
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a double-blind, multicentre, randomised, parallel group, dose-finding study of the safety, tolerability and efficacy of a three day regimen of the combination of pyronaridine/artesunate in the ratio 3:1. The primary trial objective is to determine the clinical effective dose of orally administered pyronaridine/artesunate (3:1 weight/weight) ratio in the treatment of patients with acute uncomplicated P. falciparum malaria using the PCR-corrected adequate clinical and parasitological response (ACPR) at Day 28 as primary endpoint. Secondary trial objectives are to determine the safety of once daily dosing for three (3) days of pyronaridine+artesunate (3:1) combination in male and female patients with uncomplicated P. falciparum malaria and to explore possible ethnic differences in safety or efficacy in the two regions: South East Asia and Africa

Provided treatments

  • Drug: pyronaridine/artesunate

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01594931. The sponsor of the trial is Medicines for Malaria Venture and it is looking for 477 volunteers for the current phase.
Official trial title:
A Randomised, Multi-Centre, Phase II, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria